A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 2, 2013, Pages 789-795

  Chigutsa, Emmanuel ^a   Patel, Kashyap ^b   Denti, Paolo ^a   Visser, Marianne ^c   Maartens, Gary ^a   Kirkpatrick, Carl M J ^b   McIlleron, Helen ^a   Karlsson, Mats O ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN;

ARTICLE; AUTOMATION; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL VIABILITY; BACTERIUM CULTURE; HUMAN; LIQUID CULTURE; LUNG CAVITATION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMISSION; SOUTH AFRICA; SPUTUM SMEAR; TREATMENT RESPONSE;

ANTIMALARIALS; BACTERIAL LOAD; BACTERIOLOGICAL TECHNIQUES; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; ETHAMBUTOL; HUMANS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84872844782     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01876-12     Document Type: Article

References (39)

1. Brindle R, Odhiambo J, Mitchison D. 2001. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm. Med. 1:2. doi:10.1186/1471-2466-1-2.
2. Davies GR, Khoo SH, Aarons LJ. 2006. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. J. Antimicrob. Chemother. 58:594-600.
3. Jindani A, Dore CJ, Mitchison DA. 2003. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care Med. 167:1348-1354.
4. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF. 2008. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:2831-2835.
5. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138.
6. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069.
7. Davies GR, Nuermberger EL. 2008. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb.) 88(Suppl 1):S65-S74. doi:10.1016/S1472-9792(08)70037-4.
8. Dhillon J, Lowrie DB, Mitchison DA. 2004. Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium. BMC Infect. Dis. 4:51. doi:10.1186/1471-2334-4-51.
9. Somoskovi A, Kodmon C, Lantos A, Bartfai Z, Tamasi L, Fuzy J, Magyar P. 2000. Comparison of recoveries of Mycobacterium tuberculosis using the automated BACTEC MGIT 960 system, the BACTEC 460 TB system, and Lowenstein-Jensen medium. J. Clin. Microbiol. 38:2395-2397.
10. Chew WK, Lasaitis RM, Schio FA, Gilbert GL. 1998. Clinical evaluation of the Mycobacteria Growth Indicator Tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of Mycobacterium species. J. Med. Microbiol. 47:821-827.
11. Palaci M, Ueki SY, Sato DN, Da Silva Telles MA, Curcio M, Silva EA. 1996. Evaluation of Mycobacteria Growth Indicator Tube for recovery and drug susceptibility testing of Mycobacterium tuberculosis isolates from respiratory specimens. J. Clin. Microbiol. 34:762-764.
12. Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR. 2012. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin. Microbiol. Infect. 18:711-717.
13. Pheiffer C, Carroll NM, Beyers N, Donald P, Duncan K, Uys P, van Helden P. 2008. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int. J. Tuberc. Lung Dis. 12:792-798.
14. Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, Lombard C, Donald PR, Lawrence KA, Gie RP, van Helden PD, Beyers N. 2010. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int. J. Tuberc. Lung Dis. 14:560-570.
15. Visser ME, Stead MC, Walzl G, Warren R, Schomaker M, Grewal HM, Swart EC, Maartens G. 2012. Baseline predictors of sputum culture conversion in pulmonary tuberculosis: Importance of cavities, smoking, time to detection and W-Beijing genotype. PLoS One 7:e29588. doi:10.1371 /journal.pone.0029588.
16. Mitchison DA. 1993. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 147:1062-1063.
17. Visser ME, Grewal HM, Swart EC, Dhansay MA, Walzl G, Swanevelder S, Lombard C, Maartens G. 2011. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: A randomized controlled trial. Am. J. Clin. Nutr. 93:93-100.
18. Health and Medical Publishing Group. 2010. South African medicines formulary, 9th ed, p 313. Health and Medical Publishing Group, Cape Town, South Africa.
19. Den Boon S, Bateman ED, Enarson DA, Borgdorff MW, Verver S, Lombard CJ, Irusen E, Beyers N, White NW. 2005. Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease. Int. J. Tuberc. Lung Dis. 9:1088-1096.
20. Karlsson KE, Plan EL, Karlsson MO. 2011. Performance of three estimation methods in repeated time-to-event modeling. AAPS J. 13:83-91.
21. R Development Core and Team. 2008. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
22. Gompertz B. 1825. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philos. Trans. R. Soc. Lond. 115:513-585.
23. Annadurai G, Rajesh Babu S, Srinivasamoorthy VR. 2000. Development of mathematical models (logistic, Gompertz, and Richards models) describing the growth pattern of Pseudomonas putida (NICM 2174). Bioprocess Eng. 23:607-612.
24. Zwietering MH, Jongenburger I, Rombouts FM, van't Riet K. 1990. Modeling of the bacterial growth curve. Appl. Environ. Microbiol. 56: 1875-1881.
25. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
26. Weiner M, Prihoda TJ, Burman W, Johnson JL, Goldberg S, Padayatchi N, Duran P, Engle M, Muzanye G, Mugerwa RD, Sturm AW. 2010. Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J. Clin. Microbiol. 48:4370-4376.
27. Perrin FM, Woodward N, Phillips PP, McHugh TD, Nunn AJ, Lipman MC, Gillespie SH. 2010. Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 14:1596-1602.
28. Brindle RJ, Nunn PP, Githui W, Allen BW, Gathua S, Waiyaki P. 1993. Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am. Rev. Respir. Dis. 147:958-961.
29. Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR. 2011. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS One 6:e15841. doi:10.1371/journal. pone.0015841.
30. Senkoro M, Mfinanga SG, Morkve O. 2010. Smear microscopy and culture conversion rates among smear positive pulmonary tuberculosis patients by HIV status in Dar es Salaam, Tanzania. BMC Infect. Dis. 10: 210. doi:10.1186/1471-2334-10-210.
31. Gibson AM, Bratchell N, Roberts TA. 1987. The effect of sodium chloride and temperature on the rate and extent of growth of Clostridium botulinum type A in pasteurized pork slurry. J. Appl. Bacteriol. 62:479-490.
32. Rey-Jurado E, Tudo G, Borrell S, Alcaide F, Coll P, Espanol M, Martin-Casabona N, Mick V, Montemayor M, Moure R, Salvado M, Vicente E, Gonzalez-Martin J. 2011. Impaired fitness of Mycobacterium tuberculosis resistant isolates in a cell culture model of murine macrophages. J. Antimicrob. Chemother. 66:2277-2280.
33. Cohen T, Sommers B, Murray M. 2003. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect. Dis. 3:13-21.
34. O'Sullivan DM, McHugh TD, Gillespie SH. 2010. Mapping the fitness of Mycobacterium tuberculosis strains: A complex picture. J. Med. Microbiol. 59:1533-1535.
35. Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. 2004. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:1289-1294.
36. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. 2011. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44:106-110.
37. Maisnier-Patin S, Andersson DI. 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 155:360-369.
38. Gillespie SH, Billington OJ, Breathnach A, McHugh TD. 2002. Multiple drug-resistant Mycobacterium tuberculosis: Evidence for changing fitness following passage through human hosts. Microb. Drug Resist. 8:273-279.
39. Pray L. 2008. DNA replication and causes of mutation. Nat. Educ. http://www .nature.com/scitable/topicpage/dna-replication-and-causes-of- mutation-409.